However, the Phase 3 clinical study of DCCR had mixed results, showing some positive signs for treating hyperhagia in PWS but also showing the drug was not statistically superior to a placebo. In their press release, Soleno acknowledged it is possible the FDA might ask for an additional study to be completed before granting approval. In this situation, release of the drug might be delayed.